Shares of telehealth provider Hims & Hers Health Inc. showed minimal movement in premarket trading Thursday, edging up 0.3% after closing the previous session at $15.82, a gain of 2.3%. The subdued activity follows significant regulatory and legal disclosures that have prompted analyst downgrades and cast a shadow over the company's growth prospects, particularly for its weight-loss medication offerings.
Mounting Regulatory and Legal Scrutiny
In its recently filed annual report, the company revealed it is facing a multi-front challenge. The Securities and Exchange Commission's Division of Enforcement has initiated an investigation, requesting the preservation of documents related to public statements and disclosures concerning compounded semaglutide—a key ingredient in GLP-1 weight-loss drugs—and certain business relationships. Concurrently, the company noted a referral from the Department of Health and Human Services to the Justice Department for potential violations. These developments follow a public statement from the U.S. Food and Drug Administration signaling intent to crack down on unapproved GLP-1 ingredients in compounded drugs.
Novo Nordisk Patent Lawsuit Adds Pressure
Adding to its legal woes, Hims & Hers disclosed that pharmaceutical giant Novo Nordisk A/S filed a patent infringement lawsuit against it on February 9 in Delaware federal court. The suit specifically targets compounded semaglutide GLP-1 products offered on the Hims platform. Novo Nordisk is seeking a permanent injunction that would remain in effect through the patent's expiration in December 2031, which could severely restrict Hims & Hers' ability to sell these products.
Wall Street Reacts with Downgrades
The cascade of negative news triggered immediate reactions from Wall Street analysts. BTIG Research downgraded the stock from "buy" to "neutral," citing soft first-quarter guidance and mounting legal and regulatory pressures surrounding its weight-loss medications. Separately, Citigroup slashed its price target on Hims & Hers to $13.25 from $16.50, maintaining a "sell" rating. Citi analysts expressed lingering doubts over the company's GLP-1 franchise and noted that its financial outlook for 2026 appears back-end loaded.
Strong Growth Metrics Contrast with Headwinds
The company's fundamental performance tells a different story. For the full year 2025, Hims & Hers reported revenue of $2.35 billion, representing a substantial 59% year-over-year increase. Net income reached $128 million, and its subscriber base surpassed 2.5 million. Looking ahead, management provided 2026 revenue guidance of $2.7 billion to $2.9 billion, with adjusted EBITDA projected between $300 million and $375 million. CEO Andrew Dudum has positioned the company as "well on our way to becoming the global leader in consumer health." However, the company's forecast explicitly assumes it can continue supplying compounded semaglutide and does not factor in potential benefits from its planned acquisition of Eucalyptus.
Investors Juggle Divergent Narratives
The situation presents investors with a complex, two-sided narrative. On one hand, the company's core subscription business is demonstrating rapid growth and expansion into new healthcare specialties. On the other, its promising weight-loss product segment is now hemmed in by shifting regulations, active lawsuits, and ongoing government probes. The primary risk is clear: if regulators move swiftly to impose compounding restrictions before the company can pivot consumer demand to alternative products, or if the Novo Nordisk lawsuit successfully chokes off access to semaglutide-based offerings, the company's growth projections could be significantly impaired. Furthermore, margins could face compression just as legal and operational expenses rise.
Looking Ahead: Executive Commentary on the Horizon
Market participants are awaiting further clarity from company leadership. Hims & Hers executives are scheduled to present at the Morgan Stanley Technology, Media & Telecom Conference on March 2, where they will likely face pointed questions regarding these legal and regulatory overhangs and their strategy to navigate the challenging landscape. The coming weeks will be critical in assessing whether the company's robust subscription growth can outweigh the substantial risks now embedded in its GLP-1 business.
